Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Presented by
Prof. Gill Singh, University of Hong Kong, China
Conference
ASH 2019
Maintenance therapy with arsenic trioxide (oral-As2O3), all-trans-retinoic acid (ATRA), and ascorbic acid in patients experiencing their first complete remission (CR1) from acute promyelocytic leukaemia (APL) was safe and resulted in excellent long-term survival.

Prof. Gill Singh (University of Hong Kong, China) pointed towards the lack of data on the long-term outcomes of patients receiving prolonged maintenance with oral-As2O3-based regimens in CR1 following non-arsenic-based induction [1]. In the current study, adult APL patients (median age 46) in CR1 (n=129) were recruited for maintenance treatment with oral-As2O3 (10 mg/day), ATRA (45mg/m2/day in 2 divided doses), and ascorbic acid (1 g/day) (AAA). AAA was administered for 2 weeks every 2 months for a total of 2 years. Prior induction treatment comprised ATRA (45 mg/m2/day in 2 divided doses for 42 days) and daunorubicin (50 mg/m2/day for 3 days). Consolidation comprised 2 monthly cycles of daunorubicin (50 mg/m2/day for 2 days) and cytarabine (100 mg/m2/day for 5 days).

The participants had a median follow-up of 100 (8-215) months, and 117 (90.1%) patients completed the full 2 years of AAA maintenance. Of these, 17 (13.2%) patients relapsed after a median of 19 (7-96) months from CR1 (morphologic relapse n=14; molecular relapse n=3). In total, 13 deaths occurred; 5 from refractory APL, and 8 patients died from unrelated causes (pneumonia n=4; acute myocardial infarction n=2; second malignancy n=2).

The 5-year and 10-year relapse-free survival rates were 88.8% and 85.1%, respectively. The overall survival was 94.2% for 5-years and 87.4% for 10-years. On univariate analysis, PML-RARA bcr3 (short) isoform (P=0.02), FLT3-ITD (P=0.005), and central nervous system involvement at diagnosis (P=0.002) were associated with worse relapse-free survival. On multivariate analysis, FLT3-ITD (P=0.005), and central nervous system involvement at diagnosis (P=0.004) were associated with worse relapse-free survival. On univariate analysis, PML-RARA bcr3 isoform (P=0.03), FLT3-ITD (P=0.01), and relapsed APL (P=0.002) were associated with worse OS. On multivariate analysis, therapy-related APL (P=0.03), FLT3-ITD (P=0.03), and relapsed APL (P=0.03) were associated with worse survival.

No serious safety signals were recorded. Grade 1 leukopenia occurred in 7 (5.4%) participants. The most common non-haematological toxicity was headache in 29.5% of the participants (Grade 1/2 n=38; Grade 3/4 n=0). Grade 1 hepatoxicity occurred in 7 (5.4%) participants and cutaneous herpes zoster infection occurred in 6 (4.7%) participants. The results of this study support using AAA as a maintenance therapy for APL patients in CR1.

1. Singh GH, et al. Abstract 3853, ASH 2019, 7-10 December, Orlando, USA.





Posted on